Moderated Poster Discussions - T2 Research/Science

Monday, April 13, 2026
4:30 pm - 6:15 pm

T2 Research/Science: Translation to patients, including Phase 2 and 3 clinical trials, and controlled studies leading to clinical application and evidence-based guidelines.

INTERLEUKIN 31 LEVELS IN DIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS A CROSS-SECTIONAL STUDY (Nephrology)
Mohammed Abdalkarim, MD, The University of Toledo
Chronic kidney disease—associated pruritus (CKD-aP) is a common and debilitating symptom in patients with end-stage kidney disease receiving dialysis and is associated with impaired quality of life, sleep disturbance, and increased morbidity. The pathophysiology of CKD-aP remains incompletely understood and is believed to be multifactorial, with proposed roles for metabolic abnormalities, uremic toxins, and chronic inflammation. Interleukin-31 (IL-31), a cytokine implicated in inflammatory and pruritic skin disorders, has been suggested as a potential mediator; however, its role in CKD-aP is not well established. This study aimed to assess the prevalence and severity of CKD-aP among dialysis patients and to evaluate the association between serum IL-31 levels and pruritus.